Trading for Eli Morgan was a good start, but more work should be done. Thomas Harrigan of MLB.com recently spoke about Chicago being a perfect fit for relief pitcher Carlos Estevez. He highlighted ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Eli Lilly and Company (NYSE: LLY) will attend the 43rd Annual J.P. Morgan Healthcare Conference, Jan. 13-16, 2025. David A. Ricks, Lilly chair and CEO, will participate in a fireside chat on ...

He's the third reliever to leave the AL Central champions this winter, following Eli Morgan and Nick Sandlin, who were both traded.

JPMorgan analyst Chris Schott says Eli Lilly’s (LLY) Q4 miss represents a buying opportunity as the company is positioned for strong growth in 2025. The company’s 2025 sales guidance ...

such as Eli Lilly's Zepbound or Novo Nordisk's Wegovy -- they've made headlines as demand for them soared. The obesity drug market may reach beyond $100 billion by 2030, according to Morgan ...